Mesothelioma
210
37
56
78
Key Insights
Highlights
Success Rate
68% trial completion
Published Results
42 trials with published results (20%)
Research Maturity
78 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
17.6%
37 terminated out of 210 trials
67.8%
-18.7% vs benchmark
5%
11 trials in Phase 3/4
54%
42 of 78 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 78 completed trials
Clinical Trials (210)
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
A Study of Sacituzumab Govitecan in People With Mesothelioma
SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Integrated Cancer Repository for Cancer Research
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Rapid Autopsy and Procurement of Cancer Tissue